For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Receives Approval in Japan for Additional Indication of Diagnogreen® Intravenous Injection

Tokyo, JAPAN (February 22, 2012) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it received approval in Japan for a supplemental New Drug Application (sNDA) for an additional indication of Diagnogreen® (indocyanine green, hereafter, ICG) 25 mg intravenous injection for near-infrared fluorescence angiography during cerebrovascular surgery.

A preliminary evaluation was conducted on July 29, 2011, at the meeting of the First Committee on New Drugs of the Pharmaceutical Affairs and Food Sanitation Council, and the application[1)] was permitted, leading Daiichi Sankyo to submit the sNDA for an additional indication of Diagnogreen® in August.

This indication is based on the fluorescence property of ICG in blood when illuminated by near-infrared light. ICG has been recently used for the real-time assessment of cerebral blood flow during cerebrovascular surgery, and is approved for this indication in European countries including the UK and Germany.

As a part of its CSR effort, Daiichi Sankyo is committed to making unapproved and off-label drugs available to patients who are waiting for them to be approved.

1) Application for a drug commonly known to be medically and pharmaceutically safe and with proven efficacy for which clinical trials can be partly or entirely omitted.

###